NASDAQ$ATEC

Alphatec Holdings Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

ATEC reported Q4 and full-year 2023 financial results.

Alphatec Holdings, Inc. reported Q4 2023 total revenue of $138 million. Full year 2023 total revenue grew 37% to $482 million. The company expects full year 2024 total revenue to approximate $595 million.

  • Portfolio-wide strength drove fourth quarter 2023 surgical revenue growth of 34% with an acceleration in volume growth to 29% compared to 24% in the prior quarter.
  • Expanded lateral platform with full launch of Lateral TransPsoas (LTP™) + Midline ALIF approaches and Calibrate LTX™, a lateral expandable implant.
  • Elevated the procedural sophistication of comprehensive portfolio with launch of 15 new products and line extensions in 2023.
  • Trained over 500 surgeons in 2023, contributing to a 27% increase in surgeon users compared to 2022.

Headline financials

Total Revenue

$138M

Previous: $106M+30.2%
EPS (adj)

-$0.37

Previous: -$0.33-12.1%
Adjusted EBITDA

$1.7M

No prior period
Adjusted EBITDA Margin

1.2%

No prior period
Capital Expenditures

-$28.2M

Previous: $13.5M-309.5%
Net Income

-$49.1M

Previous: -$35M-40.3%
Operating Income

-$44.8M

Previous: -$35M-28.0%
Gross Profit

$95.2M

Previous: $68.9M+38.3%
R&D Expense

$22.3M

No prior period
Stock-Based Comp

$20.5M

Previous: $10.1M+103.3%

Revenue & EPS history

Alphatec · Revenue · Quarterly

$138M

Q4 2023+30.2%vs Q4 2022
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Alphatec · $104M total across 1 segment · Q3 2023

  • Surgical Revenue
    $104M

Forward guidance

The Company continues to expect total revenue for the fiscal year ended December 31, 2024, to approximate $595 million, reflecting growth of approximately 23% compared to 2023. This includes surgical revenue of $530 million and approximately $65 million of EOS revenue. The Company expects full year 2024 non-GAAP adjusted EBITDA to approximate $22 million, which implies 560 basis points of improvement in adjusted EBITDA margin compared to full year 2023.

Tailwinds

  • Total revenue for fiscal year 2024 expected to approximate $595 million.
  • Revenue growth of approximately 23% compared to 2023.
  • Surgical revenue of $530 million.
  • EOS revenue of approximately $65 million.
  • Full year 2024 non-GAAP adjusted EBITDA to approximate $22 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

-1.5%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-0.1%

Avg return

30 days after

45%

29 / 64 earnings

Positive

+44.8%

Q3 2024

Best reaction

-43.2%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.9%-27.1%-23.3%
Q4 2025+0.5%-3.3%-21.5%
Q3 2025-0.8%+17.8%+36.7%
Q1 2025+2.4%+2.2%+2.2%
Q4 2024+9.6%+6.1%-7.9%
Q3 2024+44.8%+54.2%+93.4%
Q2 2024-32.8%-33.7%-30.2%
Q1 2024-20.2%-13.3%-22.7%
Q4 2023-7.4%-11.1%-8.6%
Q3 2023+4.7%-1.5%+20.8%
Q2 2023-7.1%-10.4%-5.2%
Q1 2023+3.1%+3.8%+4.5%
Q4 2022+1.6%+7.9%+6.3%
Q3 2022-1.5%-1.4%+9.5%
Q2 2022-0.2%-3.8%-10.9%
Q1 2022-16.1%-27.7%-34.0%
Q4 2021+3.1%+3.4%+4.4%
Q3 2021-2.2%-8.2%-18.7%
Q2 2021+2.4%-5.8%-0.2%
Q1 2021-2.0%-9.1%-8.3%
Q4 2020-7.6%+4.2%-2.1%
Q3 2020+9.4%+4.7%+22.1%
Q2 2020+21.8%+5.6%+3.1%
Q1 2020-8.0%-13.9%+5.7%
Q4 2019-8.4%-20.8%-47.2%
Q3 2019+15.2%+16.1%+18.1%
Q2 2019+9.3%+8.5%+26.2%
Q1 2019+5.4%+15.8%+8.8%
Q4 2018+14.7%+16.6%+22.1%
Q3 2018-1.7%-5.6%-13.5%
Q2 2018+4.7%+15.0%+28.1%
Q1 2018-2.0%-0.9%-1.1%
Q4 2017+0.9%-5.0%+1.2%
Q3 2017-0.8%-0.6%-30.5%
Q2 2017+2.4%+2.4%+40.2%
Q1 2017+1.9%+0.0%-4.8%
Q4 2016-16.0%-27.0%-45.8%
Q3 2016-15.8%-8.0%-12.8%
Q2 2016+2.5%+0.0%-6.5%
Q1 2016-11.8%
Q4 2015-13.8%
Q3 2015+5.8%
Q2 2015-42.6%
Q1 2015+1.4%
Q4 2014+7.4%
Q3 2014-0.7%
Q2 2014+0.0%
Q1 2014+2.3%
Q4 2013+22.3%
Q3 2013-0.5%
Q2 2013-3.9%
Q1 2013-3.2%
Q4 2012+2.6%
Q3 2012-1.8%
Q2 2012-2.5%
Q1 2012-7.4%
Q4 2011-0.5%
Q3 2011-5.6%
Q2 2011-10.4%
Q1 2011+3.7%
Q4 2010+0.4%
Q3 2010-9.6%
Q2 2010-43.2%
Q1 2010+6.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro